HRT Financial’s Black Diamond Therapeutics BDTX Stock Holding History

HRT Financial’s Portfolio BDTX Stock Details BDTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$25K	Sell	12,022 -14,329	-54%	-$34.1K	﹤0.01%	3545
2025 Q4	$64K	Buy	+26,351	New	+$93.3K	﹤0.01%	2844
2024 Q2	–	Sell	-125,094	Closed	-$634K	–	2223
2024 Q1	$634K	Buy	+125,094	New	+$504K	﹤0.01%	1134
2022 Q3	–	Sell	-10,298	Closed	-$25K	–	2806
2022 Q2	$25K	Buy	+10,298	New	+$23.9K	﹤0.01%	2578
2021 Q4	–	Sell	-71,496	Closed	-$604K	–	3193
2021 Q3	$604K	Buy	71,496 +18,487	+35%	+$183K	﹤0.01%	1813
2021 Q2	$646K	Buy	+53,009	New	+$1.05M	0.01%	1542

Other funds holding BDTX

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $43.4B AUM 51.29% 1-Year Est. Return

Mackenzie Financial Toronto Ontario, Ontario, Canada $83.3B AUM 31.19% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

HRT Financial's BDTX Position: Q1 2026 in Review

HRT Financial reduced its Black Diamond Therapeutics (BDTX) stake by 54% in Q1 2026, selling an estimated $34.1K and leaving 12,022 shares worth $25K. The position accounts for ﹤0.01% of the portfolio, ranked #3545.

HRT Financial first reported a position in BDTX in Q2 2021 and has held it in 6 quarters since. The position peaked at $646K in Q2 2021. 104 funds tracked by Wall St. Rank hold BDTX as of Q1 2026.

HRT Financial held 12,022 shares of Black Diamond Therapeutics worth $25K as of Q1 2026.
HRT Financial sold 14,329 Black Diamond Therapeutics shares in Q1 2026, an estimated $34.1K.
Black Diamond Therapeutics made up ﹤0.01% of HRT Financial's portfolio in Q1 2026, its #3545 holding.
HRT Financial first reported a position in Black Diamond Therapeutics in Q2 2021 and has held it in 6 quarters since.
HRT Financial's Black Diamond Therapeutics position peaked at $646K in Q2 2021.
104 funds tracked by Wall St. Rank held Black Diamond Therapeutics as of Q1 2026.

Based on HRT Financial's 13F filing for Q1 2026, filed 14 May 2026.